Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Bennu asteroid samples provide clues about solar system origins and 'space gum' - 2Dominating the Art of Composing: Creator Bits of knowledge
- 3Figure out how to Put resources into Lab Precious stones: A Novice's Aide
- 4Artemis 2 astronauts fly around the moon in record-breaking lunar loop by NASA
- 5Single women risk rape and exploitation in search for better life in Europe
- 5 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
- Former elite Australian soldier charged with Afghan war crimes
- Is Trump going to war with Venezuela?
- Benihana is 60 years old. Gen Z is lining up.
- Child influencers helped power a booming industry. It's time for a reckoning.
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- CPA Canada appoints eight directors as new governance model takes effect
- Several killed in Ukraine and Russia after cross-border attacks
